AngioSoma (OTCQB:SOAN) said today that it named Ken Stephenson to the Montgomery, Texas-based company’s corner office. Alexanderia Blankenship will now serve as chief operating officer and executive VP.
Stephenson has worked with hospitals, health insurance organizations and physician’s offices throughout Texas, according to the company. He previously helped set up practices for interventional radiologists and cardiologists, a perspective that AngioSoma said it hoped will help bridge the gap between its products, current standard-of-care treatments and insurance reimbursement processes.
“Working with Ken for the last month and a half, providing him due diligence, and working on AngioSoma, Inc.’s operational plan has been a pleasure,” Blankenship said in prepared remarks. I believe that Ken will be able to accelerate the company’s ability to secure funding, and bring our ‘end to end’ solution to market.”
AngioSoma touts its ‘end to end’ solution as guidance for interventional radiologists, cardiologists and internal medicine physicians regarding interventional options prior to infarction or critical limb ischemic events.
The company is also developing a pharmaceutical stabilization product, Liprostin, for the treatment of peripheral artery disease. Liprostin has completed phase I and II clinical trials and will soon enter a phase III trial, according to AngioSoma. For long-term treatment of chronic cardiovascular disease, the company has developed its Transdermal PGE-1 patch to deliver PGE-1 or Liprostin through the skin.
